We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
PureTech Health said it will begin human trials on an experimental treatment for respiratory complications following recovery from COVID-19 infections. Read More
Novartis-subsidiary AveXis has entered into an agreement to manufacture a COVID-19 vaccine being developed by Massachusetts General Hospital and Massachusetts Eye and Ear. Read More
Roche has begun a phase 3 trial of its rheumatoid arthritis treatment Actemra (tocilizumab) with Gilead Sciences’ remdesivir for treatment of patients with severe COVID-19 pneumonia. Read More
Another study — the largest to date — has shown that anti-malaria drugs hydroxychloroquine and chloroquine have no benefit in treating COVID-19, in fact have a negative effect on patient survival and are associated with an increase in ventricular arrhythmias. Read More
NIH Friday confirmed preliminary remdesivir trial data showing that the drug delivered a median recovery time of 11 days compared with 15 on placebo, establishing it as the standard of care for patients with moderate to severe disease. Read More
A leading COVID-19 vaccine candidate has shown promise as being safe and effective in humans and produced an immune response against the coronavirus, according to preliminary data from a phase 1 trial of 108 healthy adults in China. Read More